DPP4 inhibitor vildagliptin preserves β-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice

Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

(2010) B. Ahren et al.   DIABETES CARE

A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis

(2010) Jae Min Cho et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats

(2010) Alokesh Duttaroy et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

A GIP Receptor Agonist Exhibits β-Cell Anti-Apoptotic Actions in Rat Models of Diabetes Resulting in Improved β-Cell Function and Glycemic Control

(2010) Scott B. Widenmaier et al.   PLoS One

Glucagon-Like Peptide-1 Agonists Protect Pancreatic β-Cells From Lipotoxic Endoplasmic Reticulum Stress Through Upregulation of BiP and JunB

(2009) Daniel A. Cunha et al.   DIABETES

Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes

(2009) James Mu et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Ablation of C/EBPβ alleviates ER stress and pancreatic β cell failure through the GRP78 chaperone in mice

(2009) Tomokazu Matsuda et al.   JOURNAL OF CLINICAL INVESTIGATION